COMMUNIQUÉS West-GlobeNewswire

Palvella Therapeutics to Present at Upcoming Healthcare Investor Conferences
28/08/2025
WAYNE, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients [...]
Zevra Therapeutics Announces Multiple Datasets on MIPLYFFA® (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM)
28/08/2025
CELEBRATION, Fla., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, [...]
Pasithea Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
28/08/2025
MIAMI, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, [...]
Tenax Therapeutics to Participate in the Cantor Global Healthcare Conference 2025
28/08/2025
CHAPEL HILL, N.C., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to [...]
Akero Therapeutics to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
28/08/2025
SOUTH SAN FRANCISCO, Calif., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked [...]
Trading by management and close relations of management
28/08/2025
Please read the announcement in PDF Attachment 2025_41_Trading_By_Management
TOLREMO therapeutics Receives Two FDA Fast Track Designations for TT125-802 in Pretreated, Advanced or Metastatic NSCLC With Either an EGFR or a KRAS-G12C Mutation
28/08/2025
TT125-802 is a small molecule CBP/p300 bromodomain inhibitor that shows clinical activity as single agent in solid tumors, including advanced EGFR-mutated and KRAS-G12C-mutated non-small cell lung cancer (NSCLC) 1 in 5 [...]
Oculis to Participate in Upcoming September Investor Conferences
28/08/2025
ZUG, Switzerland, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on developing innovative solutions for ophthalmic and neuro- [...]
Oculis to Participate in Upcoming September Investor Conferences
28/08/2025
ZUG, Switzerland, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on developing innovative solutions for ophthalmic and neuro- [...]
argenx to Present at Upcoming Investor Conferences
28/08/2025
August 28, 2025 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that [...]
IBA reports strong Half Year 2025 results, transforming towards a more profitable business
28/08/2025
Read the entire half year 2025 results press release here Louvain-la-Neuve, Belgium, 28 August 2025 - IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology, today announces its [...]
IBA réalise des résultats solides au premier semestre 2025, évoluant vers une plus haute profitabilité
28/08/2025
Cliquez ici pour lire l'intégralité du communiqué de presse des résultats du premier semestre 2025 Louvain-La-Neuve, Belgique, 28 août 2025 - IBA (Ion Beam Applications S.A.), le leader mondial de la technologie d’ [...]
Idorsia’s TRYVIO – First FDA-approved therapy to target the endothelin pathway for systemic hypertension
28/08/2025
Allschwil, Switzerland – August 28, 2025 Idorsia Ltd (SIX: IDIA) releases an OnDemand investor webcast outlining how TRYVIO™ (aprocitentan) – the first and only hypertension therapy targeting the endothelin pathway – [...]
International Observers Raise Concerns Over Judicial Irregularities in Senegal; Rights Advocates Stress Importance for Governance and Investment
28/08/2025
Khadim Ba, a Non-Executive Director at DerMond Oil & Gas LOS ANGELES, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Independent legal experts and rights monitors are raising concerns over the ongoing detention and judicial [...]
Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock
28/08/2025
- The offering was made to two new fundamental institutional investors - - The Company intends to use the net proceeds to fund preparation for our Phase 3 programs of zervimesine in neurodegenerative disorders - [...]
Tilray Brands Successfully Regains Compliance with Nasdaq’s Minimum Bid Price Requirement
27/08/2025
NEW YORK and LEAMINGTON, Ontario, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a global consumer packaged goods company at the forefront of the cannabis, [...]
Curanex Pharmaceuticals Inc. Announces Closing of its Initial Public Offering
27/08/2025
Jericho, New York, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) ("Curanex" or the "Company"), a developmental stage pharmaceutical company focused on discovering and developing botanical [...]
Tarsus to Participate in Upcoming Investor Conferences
27/08/2025
IRVINE, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management plans to participate in the following upcoming investor conferences: Wells Fargo 20 th [...]
Jasper Therapeutics to Present at Upcoming Investor Conferences
27/08/2025
REDWOOD CITY, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting [...]

Pages